Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284569 | 0.92 | RORC (0.41) | RORCCD274KMT2ADRD2HTR2A | |
| SCHEMBL4284328 | 0.90 | RORC (0.41) | RORCCD274GSK3BKDM4EDRD2 | |
| SCHEMBL4288246 | 0.87 | RORC (0.40) | RORCCD274GSK3BKDM4EDRD2 | |
| SCHEMBL4279917 | 0.86 | GSK3B (0.51) | RORCCD274KMT2AGSK3BKDM4E | |
| SCHEMBL4289295 | 0.84 | RORC (0.45) | RORCCD274GSK3B | |
| SCHEMBL4287697 | 0.83 | RORC (0.44) | RORC | |
| SCHEMBL4290861 | 0.83 | MAPT (0.43) | CD274KMT2AKDM4E | |
| SCHEMBL4290584 | 0.78 | CD274 (0.39) | CD274KMT2A | |
| SCHEMBL4281645 | 0.77 | CD274 (0.41) | CD274KMT2AFGFR1DDR2 | |
| SCHEMBL4288766 | 0.77 | CD274 (0.42) | CD274KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | RORC 20/4885CD274 2230/4885KMT2A 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.